FDA blesses Novartis TOBI Podhaler for lung bacteria in CF
This article was originally published in Scrip
Executive Summary
The US FDA on 22 March granted its approval to Swiss drug maker Novartis to market TOBI Podhaler (tobramycin inhalation powder) as a therapy to manage cystic fibrosis (CF) patients infected with the bacterium Pseudomonas aeruginosa, the leading cause of loss of lung function in CF, an autosomal recessive, progressive and usually fatal genetic disease, which affects about 30,000 Americans.